Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 589 | 241 | 225 |
| Samples | 359 | 181 | 158 |
| Peptides | 465 | 225 | 126 |
Function
MYCBP2 · MYC binding protein 2
This gene encodes an E3 ubiquitin-protein ligase and member of the PHR (Phr1/MYCBP2, highwire and RPM-1) family of proteins. The encoded protein plays a role in axon guidance and synapse formation in the developing nervous system. In mammalian cells, this protein regulates the cAMP and mTOR signaling pathways, and may additionally regulate autophagy. Reduced expression of this gene has been observed in acute lymphoblastic leukemia patients and a mutation in this gene has been identified in patients with a rare inherited vision defect. [provided by RefSeq, Mar 2017].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000544440 | O75592 | 359 | 315 |
| ENST00000683823 | A0A804HIR9* | 121 | 121 |
| ENST00000357337 | A0A499FJI4* | 109 | 82 |
Gene Properties
Recurrent Mutations
All 315 amino-acid changes on canonical ENST00000544440 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MYCBP2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MYCBP2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 14/612 2% |
| Unknown | 0/10 0% | 1/29 3% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 16/1390 1% |
| Ovarian Carcinoma | 10/109 9% | 10/998 1% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Melanoma | 10/210 5% | 21/1899 1% |
| Rhabdomyosarcoma | 3/33 9% | 0/171 0% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Colorectal Carcinoma | 27/143 19% | 20/3239 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Neuroendocrine Tumour | 7/154 5% | 1/577 0% |
| Head and Neck Carcinoma | 8/85 9% | 8/1574 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Bladder Carcinoma | 3/58 5% | 5/956 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 3/810 0% |
| Other Solid Cancers | 3/94 3% | 7/1515 0% |
| Hepatocellular Carcinoma | 4/46 9% | 9/2210 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Non-Cancerous | 3/104 3% | 2/830 0% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 8/2550 0% |
| Gastric Carcinoma | 5/74 7% | 4/1809 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 5/1592 0% |
Mutation Distribution
Where MYCBP2 is mutated · all tissues, split by cell line vs tissue
How many mutations in MYCBP2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 589 mutations in MYCBP2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|